BC Platforms signs a co-operation agreement with Cloudlynx for GxP validated cloud services

BASEL, SWITZERLAND - Apr 14, 2015 - A collaboration agreement where Cloudlynx provides cloud services for the BC Platforms software solutions was announced today at the Swiss Biotech Day 2015 in Basel.

Different types of cancers are a growing burden in today's world. Genetic research in diagnosis, prevention and treatment of a cancer is vitally important within academia and life sciences industry. With research and development, the intention in the future is to deliver best possible treatment for an individual patient and move towards personalized medicine.

In order to achieve the goal, there is a need to gather information about different types of cancer, the progression of the disease and the treatment received. BC Platforms’ data management solution is helping R&D to reach its goals faster by making data management, sharing and analysis easier and more efficient than ever before.

Some techniques are particularly promising, like the use of cloud computing to address the massive amount of data. BC Platforms and Cloudlynx have signed an agreement where Cloudlynx provides GxP validated cloud services for BC Platforms’ software solutions.

BC Platforms offers versatile modules for clinical and genomic data management, as well as sample tracking. Modules are delivered as hosted Software as a Service (SaaS) solutions. The platform has been designed to scale up and to solve the big genome data challenges cost-effectively by using innovative data splitting and massively parallel genomic data analysis workflows to serve clients in pharmaceutical industry, academic research and healthcare.

Cloudlynx’s Infrastructure as a Service (IaaS) has been built to cater for GxP applications and requirements and it uses the highest standard of encryption, like for banking business.

“Some of our customers have a clear need to comply with GxP practices, including the ability to perform audits and permit authorities to execute inspections. A highly specialized and quality-driven partner enables us to place our cloud product offering in such environment”, states Tero Silvola, CEO of BC Platforms.

More information:

Tero Silvola CEO, BC Platforms, tel. +358 40 590 5733, email: tero.silvola@bcplatforms.com

Serge Meyer, CEO, Cloudlynx, tel. +41 61 500 12 12, email: serge.meyer@cloundlynx.ch

About BC Platforms

BC Platforms Ltd (est. in 1997) develops clinical and genomic data integration and analysis software. Our software is used in genomic research, genetic counseling, pharmacogenomics, agrigenomics, preventive and personalized medicine and biobanking. We provide customized solutions for pharmaceutical and biotech companies that utilize genomic data in their R&D. BC Platforms serves a wide international customer base in 18 countries and three continents. Our customers consist of top-tier research groups, international cohort studies, biobanks and major pharmaceutical companies that collect and analyze genotype and phenotype data. The company headquarters is located in Finland and we have sales offices in Canada, England, Switzerland and the U.S.

About Cloudlynx

Cloudlynx is a highly compliant Swiss cloud provider offering IaaS especially to regulated industries (pharma, banking and government). Benefits include single legal jurisdiction, strong security, real rapid elasticity and GxP compliance.